The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

The DAMO PANDA can accurately detect pancreatic cancer lesions, and FDA breakthrough therapy designation aims to accelerate ...

For many cancer patients, side effects from radiation can be debilitating. But a new way of delivering radiation treatment has proven effective at eliminating a hard-to-treat cancer with the only side ...

“The approval of this treatment offers patients more options and the chance to control their disease.” “Dupixent is the first new targeted treatment ... “With this FDA decision, Dupixent ...

Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application ...

Casale, MD The FDA approved dupilumab ... despite histamine-1 antihistamine treatment, according to a company press release. “Dupixent is the first new targeted treatment for chronic spontaneous ...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab ... Officer at Regeneron “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

Dupilumab offers a new treatment option for CSU, being the first targeted therapy ... Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ..